Share on StockTwits

Shares of Boston Scientific (NYSE:BSX) have been given an average recommendation of “Buy” by the twenty-seven analysts that are currently covering the stock, Analyst Ratings Network reports. Eight analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $13.31.

A number of analysts have recently weighed in on BSX shares. Analysts at TheStreet upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Thursday, May 1st. Separately, analysts at Citigroup Inc. reiterated a “hold” rating on shares of Boston Scientific in a research note on Wednesday, April 30th. They now have a $13.80 price target on the stock. Finally, analysts at RBC Capital raised their price target on shares of Boston Scientific from $14.00 to $15.00 in a research note on Wednesday, April 23rd. They now have an “outperform” rating on the stock.

In other Boston Scientific news, Director Ernest Mario unloaded 10,000 shares of Boston Scientific stock on the open market in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $12.58, for a total value of $125,800.00. Following the completion of the transaction, the director now directly owns 317,855 shares of the company’s stock, valued at approximately $3,998,616. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Boston Scientific (NYSE:BSX) traded down 0.94% during mid-day trading on Friday, hitting $12.68. 1,172,208 shares of the company’s stock traded hands. Boston Scientific has a 52-week low of $8.36 and a 52-week high of $14.08. The stock has a 50-day moving average of $13.23 and a 200-day moving average of $12.66. The company has a market cap of $16.769 billion and a price-to-earnings ratio of 46.89.

Boston Scientific (NYSE:BSX) last released its earnings data on Tuesday, April 29th. The company reported $0.16 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.18 by $0.02. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company posted $0.16 earnings per share. The company’s quarterly revenue was up .7% on a year-over-year basis. Analysts expect that Boston Scientific will post $0.81 EPS for the current fiscal year.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.